Rahvar Mostafa, Manoochehrabadi Tahereh, Ahmadi Lakalayeh Gholamreza, Barzegar Zeynab, Karimi Roya, Ghanbari Hossein
Department of Medical Nanotechnology, Faculty of Advanced Technologies in Medicine, Iran University of Medical Sciences, Tehran 14496-14535, Iran.
Cellular and Molecular Research Center, Iran University of Medical Sciences, Tehran 14496-14535, Iran.
ACS Appl Mater Interfaces. 2025 Jan 22;17(3):4579-4594. doi: 10.1021/acsami.4c17930. Epub 2025 Jan 8.
Despite the unique properties of clay nanocomposites for cardiovascular applications, there are few data on the hemocompatibility of these nanomaterials. This study represents the first comprehensive investigation of the hemo/biocompatibility of clay nanocomposites . Nanocomposite coatings of polylactic acid (PLA)-polyethylene glycol (3 wt %)-Cloisite20A nanoclay (3 wt %) were produced using electrospraying technique as potential drug-eluting stent (DES) coatings. Pristine PLA coating served as a control. The coatings ' different structural and biological properties were assessed, including surface morphology, topography, hydrophobicity, mechanics, and the interaction of nanocomposites with blood components, endothelial cells (EC), and bacteria. Findings indicated that all of the coatings were highly hydrophobic with microbead/nanofiber morphology and had antifouling properties. The absorption profiles of plasma proteins were similar for all groups, and nanocomposites did not trigger the coagulation cascade and complement activation. The nanocomposites did not increase hemolysis or platelet and leukocyte adhesion and activation. Interestingly, the nanocomposites exhibited the lowest levels of interleukin-6 production. Cellular experiments showed that the nanocomposites did not reduce ECs survival compared to the control group, and a continuous layer of ECs covered the nanocomposite surfaces after 4 days. These results demonstrate the exceptional hemo/biocompatibility of as-prepared clay nanocomposites as promising biomaterials for implants such as DESs.
尽管粘土纳米复合材料在心血管应用方面具有独特性能，但关于这些纳米材料血液相容性的数据却很少。本研究首次对粘土纳米复合材料的血液/生物相容性进行了全面调查。使用电喷雾技术制备了聚乳酸（PLA）-聚乙二醇（3 wt%）-Cloisite20A纳米粘土（3 wt%）的纳米复合涂层，作为潜在的药物洗脱支架（DES）涂层。原始PLA涂层用作对照。评估了涂层不同的结构和生物学特性，包括表面形态、形貌、疏水性、力学性能以及纳米复合材料与血液成分、内皮细胞（EC）和细菌的相互作用。研究结果表明，所有涂层均具有微珠/纳米纤维形态且高度疏水，并具有防污性能。所有组的血浆蛋白吸收情况相似，纳米复合材料未引发凝血级联反应和补体激活。纳米复合材料未增加溶血、血小板及白细胞的黏附与激活。有趣的是，纳米复合材料产生的白细胞介素-6水平最低。细胞实验表明，与对照组相比，纳米复合材料未降低内皮细胞的存活率，且4天后纳米复合材料表面覆盖了一层连续的内皮细胞。这些结果证明了所制备的粘土纳米复合材料具有出色的血液/生物相容性，是用于如药物洗脱支架等植入物的有前景的生物材料。
